Sebastián Forero Amézquita

Sebastián Forero Amézquita

Auto-generated profile, based on publicly available information

Sebastián Forero Amézquita

Faculty of Medicine, Universidad de La Sabana, Chía, Colombia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2023 in Genes
Verified
Journal Article
Open access
PDF file
MAMarisol Aguirre
Marisol Aguirre
MEManuela Escobar
Manuela Escobar
SASebastián Forero Amézquita
Sebastián Forero Amézquita
DCDavid Cubillos
David Cubillos
CRCamilo Rincón
Camilo Rincón
LRLuis Gustavo Celis Regalado
Luis Gustavo Celis Regalado
The transcription factors Oct4, Sox2, Klf4, and c-Myc enable the reprogramming of somatic cells into induced pluripotent cells. Reprogramming generates newly differentiated cells for potential therapies in cancer, neurodegenerative diseases, and rejuvenation processes. In cancer therapies, these transcription factors lead to a reduction in the size and aggressiveness of certain tumors, such as sarcomas, and in neurodegenerative diseases, they enable the production of dopaminergic cells in Parkinson’s disease, the replacement of affected neuronal cells in olivopontocerebellar atrophy, and the regeneration of the optic nerve. However, there are limitations, such as an increased risk of cancer development when using Klf4 and c-Myc and the occurrence of abnormal dyskinesias in the medium term, possibly generated by the uncontrolled growth of differentiated dopaminergic cells and the impairment of the survival of the new cells. Therefore, the Yamanaka transcription factors have shown therapeutic potential through cell reprogramming for some carcinomas, neurodegenerative diseases, and rejuvenation. However, the limitations found in the studies require further investigation before the use of these transcription factors in humans.

26 February 2025 in The Journal of Medicine Access
Verified
Journal Article
Open access
CRCamilo Andrés Rincón Romero
Camilo Andrés Rincón Romero
SASebastián Forero Amézquita
Sebastián Forero Amézquita
JCJulio César Velasco Castro
Julio César Velasco Castro
LALorena García Agudelo
Lorena García Agudelo
Stokes-Adams syndrome is defined as a transient loss of consciousness with spontaneous recovery after a decrease in cardiac output that leads to a state of cerebral hypoxia and may cause seizures. It is a rare and poorly documented condition. High-degree atrioventricular block, paroxysmal ventricular arrest, and pulseless ventricular tachycardia have been described as causes, and depending on the case, temporary or permanent pacemaker implantation or cardiac defibrillation may be necessary. We present the case of a 78-year-old male patient with Stokes-Adams syndrome secondary to 2:1 atrioventricular block requiring definitive pacemaker implantation without recurrence of syncopal or convulsive episodes. It is important to consider Stokes-Adams syndrome as a possible cause of syncope or seizures and that the recognition of this disease through an adequate clinical history and interpretation of paraclinical tests can save lives due to the risk of sudden death. There is not much information about this syndrome, since there are few cases reported in the literature.